Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
Add more filters











Publication year range
2.
Scand J Rheumatol ; 34(6): 480-4, 2005.
Article in English | MEDLINE | ID: mdl-16393773

ABSTRACT

OBJECTIVE: RANKL is known to play an important role in activating osteoclasts and advancing the progress of osteoporosis. However, little is known about the effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Our study was intended to clarify effects of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. METHODS: Human T lymphoblastic cell line Jurkat and human osteosarcoma cell line MG-63 were used for the following experiments. RANKL expression in two cell lines was measured using reverse transcription polymerase chain reaction (RT-PCR) analysis and enzyme immunoassay (EIA). Luciferase assays using pGRE-Luc were also performed. RESULTS: In Jurkat and MG-63 cells, dexamethasone induced expression of soluble RANKL (sRANKL) protein in supernatants and RANKL mRNA in cells. Moreover, bisphosphonates, but not cyclooxygenase inhibitors, repressed dexamethasone-induced sRANKL protein production. By contrast, glucocorticoid receptor-driven transcriptional activity was not inhibited by bisphosphonates. CONCLUSION: Glucocorticoid induced RANKL expression in human cells derived from T lymphocytes and osteoblasts. Bisphosphonates inhibited glucocorticoid-induced RANKL expression, suggesting that these effects might be a new therapeutic mechanism for bisphosphonates.


Subject(s)
Bone Density Conservation Agents/pharmacology , Carrier Proteins/genetics , Dexamethasone/pharmacology , Diphosphonates/pharmacology , Glucocorticoids/pharmacology , Membrane Glycoproteins/genetics , Anti-Inflammatory Agents/pharmacology , Carrier Proteins/metabolism , Gene Expression/drug effects , Humans , Jurkat Cells/drug effects , Jurkat Cells/metabolism , Membrane Glycoproteins/metabolism , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteosarcoma/drug therapy , Osteosarcoma/metabolism , RANK Ligand , RNA, Messenger/metabolism , Receptor Activator of Nuclear Factor-kappa B , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism
3.
Ann Rheum Dis ; 61(9): 834-7, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12176812

ABSTRACT

OBJECTIVE: To examine the effects of thrombin on RANTES mRNA expression through protease activated receptor in synovial fibroblasts in patients with rheumatoid arthritis (RA). METHODS: A semiquantitative reverse transcriptase-polymerase chain reaction and reporter gene assay were performed using cultured human synovial fibroblasts from patients with RA. The up regulatory effects of thrombin on RANTES mRNA expression were tested. In addition, the roles of protease activated receptors (PARs) were analysed. RESULTS: PAR-1 and PAR-3, but not PAR-4, were expressed in synovial fibroblasts. Thrombin induced RANTES mRNA expression in a time dependent manner in synovial fibroblasts expressing PAR-1. A reporter gene assay showed that thrombin-induced RANTES gene expression was through PAR-1, but not PAR-3. CONCLUSIONS: Thrombin induced RANTES mRNA expression through a PAR-1 mediated pathway, possibly indicating that thrombin has an important role in migration of inflammatory cells by RANTES to the synovium in patients with RA.


Subject(s)
Arthritis, Rheumatoid/metabolism , Caenorhabditis elegans Proteins , Chemokine CCL5/genetics , Intracellular Signaling Peptides and Proteins , Protein Serine-Threonine Kinases/metabolism , RNA, Messenger/metabolism , Synovial Membrane/metabolism , Thrombin/pharmacology , Apoptosis Regulatory Proteins , Carrier Proteins/analysis , Carrier Proteins/genetics , Cells, Cultured , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Expression/drug effects , HeLa Cells , Helminth Proteins/analysis , Helminth Proteins/genetics , Humans , Protein Serine-Threonine Kinases/genetics , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Transfection , beta-Galactosidase/genetics
4.
Mod Rheumatol ; 12(1): 37-43, 2002 Mar.
Article in English | MEDLINE | ID: mdl-24383830

ABSTRACT

Abstract We investigated the role of nuclear factor (NF)-κB on tumor necrosis factor (TNF)-α-induced regulated upon activation, normal T-cell expressed and secreted (RANTES) expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis (RA). Using cultured human fibroblast-like synoviocytes from patients with RA, semiquantitative reverse transcriptase-polymerase chain reaction, electrophoretic mobility shift assay, and Western blot were performed for RANTES expression, NF-κB activation, and degradation of IκB, respectively. In addition, the transcriptional effect of TNF-α on RANTES gene expression was analyzed by reporter gene assay. We found that TNF-α clearly induced RANTES protein production and expression of RANTES mRNA in a time-dependent manner. Furthermore, TNF-α persistently induced NF-κB activation caused by IκBα and IκBß1 degradation. Supershift analysis revealed that TNF-α-induced DNA-binding complexes were composed principally of the p65 and p50 Rel family members. Moreover, transcriptional activation of the RANTES promoter by TNF-α was dependent on specific NF-κB response elements that were regulated by NF-κB. Results herein indicate that NF-κB activation caused by degradation of IκBα and IκBß1 by TNF-α increased RANTES gene expression in fibroblast-like synoviocytes, suggesting that NF-κB plays an important role in the migration of inflammatory cells by RANTES to the synovium in patients with rheumatoid arthritis.

5.
Biochem Biophys Res Commun ; 288(5): 1095-101, 2001 Nov 16.
Article in English | MEDLINE | ID: mdl-11700023

ABSTRACT

Regulated upon activation, normal T-cells expressed and secreted (RANTES) mainly migrates memory type CD4+ T-lymphocytes to inflamed tissues. In this study, we examined effects of bile acids on RANTES gene expression in human hepatoma cells. Upon stimulation with hydrophobic bile acids, RANTES proteins were clearly increased. Semiquantitative RT-PCR analysis revealed that chenodeoxycholic acid (CDCA) induced RANTES mRNA expression. Moreover, RANTES was transcriptionally induced in two hepatoma cell lines by CDCA, presumably via its cognate NF-kappaB binding sites in the RANTES promoter. Electrophoretic mobility shift assay revealed that hydrophobic bile acids induced DNA-binding activity of NF-kappaB. Additionally, the magnitude of inducibility was closely associated with the hydrophobicity of bile acids. In conclusion, we might indicate that bile acids induced RANTES gene expression in human hepatoma cells, possibly suggesting that bile acids play an important role in migration of inflammatory cells by RANTES to the liver in patients with primary biliary cirrhosis.


Subject(s)
Bile Acids and Salts/physiology , Chemokine CCL5/genetics , NF-kappa B/metabolism , Transcriptional Activation , Antibodies/immunology , Bile Acids and Salts/chemistry , Binding Sites , Chemokine CCL5/biosynthesis , Chemokine CCL5/immunology , Chenodeoxycholic Acid/pharmacology , Electrophoretic Mobility Shift Assay , Humans , Hydrophobic and Hydrophilic Interactions , Kinetics , Liver Cirrhosis, Biliary/immunology , NF-kappa B/physiology , Promoter Regions, Genetic , RNA, Messenger/biosynthesis , Tumor Cells, Cultured
6.
Auton Neurosci ; 91(1-2): 96-9, 2001 Aug 13.
Article in English | MEDLINE | ID: mdl-11515806

ABSTRACT

The present study examined the effects of cervical spinal manipulation, a widely applied form of physical therapy, which involves innocuous mechanical stimulation, on heart rate and heart-rate variability, in a cohort of healthy young adults. Using a cross-over treatment design, with a one-week washout period and, in contrast to a sham procedure, the authentic manipulation produced significant alterations in both heart rate and measures of heart-rate variability calculated from power spectrum analysis. In particular, there was an increase in the ratio of low-frequency (LF)-to-high-frequency (HF) components of the power spectrum of heart-rate variability, which may reflect a shift in balance between sympathetic and parasympathetic output to the heart.


Subject(s)
Autonomic Nervous System/physiology , Heart Rate/physiology , Manipulation, Spinal , Adult , Cohort Studies , Cross-Over Studies , Female , Humans , Male , Mechanoreceptors/physiology , Neck , Reference Values
7.
J Rheumatol ; 27(12): 2777-85, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11128663

ABSTRACT

OBJECTIVE: To examine the effect of thrombin on nuclear factor (NF)-kappaB activation and cell proliferation in synovial cells from patients with rheumatoid arthritis (RA). METHODS: Using cultured human synovial cells from patients with RA, electrophoretic mobility shift assay, [3H]thymidine incorporation assay, and MTT assay were performed. We tested the upregulatory effects of thrombin on NF-kappaB activation and cell proliferation. The effect of thrombin on degradation of IkappaB was analyzed by Western blot. RESULTS: Thrombin transiently induced DNA-binding activity of NF-kappaB, followed by degradation of IkappaBalpha, but not IkappaBbeta1. Moreover, synovial cell proliferation was stimulated by thrombin in a dose dependent manner. The kinetics of synovial cell proliferation induced by thrombin were almost parallel to those of NF-kappaB activation. Supershift analysis revealed that thrombin induced DNA-binding complexes were made up principally of the p65 and p50 Rel family members. Further, protein kinase C inhibitor calphostin C repressed thrombin induced NF-kappaB activation and cell proliferation in synovial cells. CONCLUSION: Thrombin stimulates synovial cell proliferation involved in NF-kappaB activation, at least in part, through a protein kinase C mediated pathway, possibly indicating that thrombin plays an important role in synovial hyperplasia in RA.


Subject(s)
Arthritis, Rheumatoid/pathology , I-kappa B Proteins , NF-kappa B/metabolism , Protein Kinase C/metabolism , Synovial Membrane/metabolism , Thrombin/physiology , Antithrombins/pharmacology , Arthritis, Rheumatoid/metabolism , Cell Division/drug effects , Cell Division/physiology , Cells, Cultured , DNA/drug effects , DNA/metabolism , DNA-Binding Proteins/metabolism , Enzyme Inhibitors/pharmacology , Fibroblasts/metabolism , Humans , NF-KappaB Inhibitor alpha , Protein Kinase C/antagonists & inhibitors , RNA, Messenger/metabolism , Receptors, Thrombin/genetics , Receptors, Thrombin/metabolism , Synovial Membrane/drug effects , Synovial Membrane/enzymology , Synovial Membrane/pathology , Thrombin/metabolism
8.
Intern Med ; 38(6): 512-5, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10411360

ABSTRACT

A case of human T cell leukemia virus type I (HTLV-1) associated myelopathy (HAM)/tropical spastic paraparesis (TSP) with 14-year history of systemic lupus erythematosus (SLE) is reported. For 9 years, the numbness of the feet and sacral region progressed with occasional urinary incontinence and constipation. She was admitted to hospital due to gait disturbance and aggravation of SLE and the diagnosis of HAM/TSP was confirmed, indicating that HTLV-1 infection is associated with the development of not only HAM/TSP but also SLE.


Subject(s)
Lupus Erythematosus, Systemic/etiology , Paraparesis, Tropical Spastic/complications , Blotting, Western , Brain/pathology , DNA, Viral/analysis , Deltaretrovirus Antibodies/analysis , Diagnosis, Differential , Female , Human T-lymphotropic virus 1/genetics , Human T-lymphotropic virus 1/immunology , Human T-lymphotropic virus 1/pathogenicity , Humans , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/virology , Magnetic Resonance Imaging , Middle Aged , Paraparesis, Tropical Spastic/diagnosis , Paraparesis, Tropical Spastic/virology , Polymerase Chain Reaction , Spinal Cord/pathology
9.
Oncogene ; 18(22): 3316-23, 1999 Jun 03.
Article in English | MEDLINE | ID: mdl-10362352

ABSTRACT

The proto-oncoprotein Bcl-3 is a member of the IkappaB family and is present predominantly in the nucleus. To gain insight into specific nuclear functions of Bcl-3 we have isolated proteins that interact with its ankyrin repeat domain. Using the yeast two-hybrid-system we identified four novel binding partners of Bcl-3 in addition to NF-kappaB p50 and p52, previously known to associate with Bcl-3. The novel Bcl-3 interactors Jab1, Pirin, Tip60 and Bard1 are nuclear proteins which also bind to other transcription factors including c-Jun, nuclear factor I (NFI), HIV-1 Tat or the tumor suppressor and PolII holoenzyme component Brca1, respectively. Bcl-3, p50, and either Bard1, Tip60 or Pirin are sequestered into quarternary complexes on NF-kappaB DNA binding sites, whereas Jab1 enhances p50-Bcl-3-DNA complex formation. Furthermore, the histone acetylase Tip60 enhances Bcl-3-p50 activated transcription through an NF-kappaB binding site, indicating that quarternary complexes containing Bcl-3 interactors modulate NF-kappaB driven gene expression. These data implicate Bcl-3 as an adaptor between NF-kappaB p50/p52 and other transcription regulators and suggest that its gene activation function may at least in part be due to recruitment of the Tip60 histone actetylase.


Subject(s)
Acetyltransferases , NF-kappa B/metabolism , Nuclear Proteins/metabolism , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , Animals , Ankyrins/metabolism , B-Cell Lymphoma 3 Protein , Binding Sites , COP9 Signalosome Complex , Carrier Proteins/genetics , Carrier Proteins/metabolism , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Dioxygenases , HeLa Cells/metabolism , Histone Acetyltransferases , Humans , I-kappa B Proteins , Intracellular Signaling Peptides and Proteins , Lysine Acetyltransferase 5 , Mutation , NF-kappa B/genetics , NF-kappa B p50 Subunit , Nuclear Proteins/genetics , Peptide Hydrolases , Proteins/genetics , Proteins/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Repetitive Sequences, Amino Acid , Transcription Factors/genetics , Transcription Factors/metabolism , Transcriptional Activation , Yeasts/genetics
10.
J Dent Res ; 78(1): 69-76, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10065948

ABSTRACT

In inflamed periodontal lesions, dense infiltration of lymphocytes is usually observed in the extravascular periodontal connective tissue, adjacent to gingival fibroblasts. Our previous study revealed that activated lymphocytes can adhesively interact with gingival fibroblasts in vitro. In the present study, we investigated whether gingival fibroblasts are activated through direct interaction with lymphoid cells by monitoring the expression of inflammatory cytokine mRNA in human gingival fibroblasts (HGF). Co-culture with various human lymphoid cells in vitro resulted in a marked increase in the expression of IL-1alpha, IL-1beta, and IL-6 mRNA by the HGF. In addition, expression of the mRNA of the IL-1beta-converting enzyme (ICE), which is essential to produce the mature form of IL-1beta, was constitutively observed in the HGF, suggesting that mature IL-1beta is produced by these cells. When HGF were cultured with the culture supernatant of the lymphoid cells, the increase in the inflammatory cytokine mRNA expression was not observed. Similarly, when HGF and lymphoid cells were cultured in the same well but separated by a membrane which prevented direct contact between the cells, no increase in inflammatory cytokine mRNA expression was observed. These results strongly indicate that direct interaction between these heterotypic cell types transduces activation signals into HGF that induce an increase in inflammatory cytokine mRNA expression. Furthermore, IL-1beta mRNA expression in the HGF was synergistically increased when HGF directly interacted with lymphoid cells in the presence of exogeneous IL-1beta. The present study demonstrates that direct interaction between HGF and lymphoid cells stimulates HGF to increase inflammatory cytokine mRNA expression, and raises the possibility that heterotypic cell-cell interaction may facilitate local inflammatory reactions.


Subject(s)
Fibroblasts/immunology , Gingiva/metabolism , Inflammation Mediators/metabolism , Interleukin-1/biosynthesis , T-Lymphocytes/physiology , Caspase 1/biosynthesis , Cells, Cultured , Coculture Techniques , Densitometry , Fibroblasts/metabolism , Gingiva/cytology , Gingiva/immunology , Humans , Interleukin-6/biosynthesis , Periodontitis/immunology , Periodontitis/metabolism , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Tumor Cells, Cultured
11.
Immunopharmacology ; 39(1): 31-8, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9667421

ABSTRACT

We investigated the effect of EPC-K1, which is a phosphodiester compound of vitamin E and vitamin C, on NF-kappaB activity in human cultured astrocytoma cells T98G. In TNFalpha-stimulated T98G cells, treatment with EPC-K1 inhibited both DNA binding activity and transactivation of NF-kappaB in a dose-dependent manner, and the suppressive effect of EPC-K1 was stronger than either that of vitamin E or vitamin C. Moreover, we showed that in TNFalpha-stimulated T98G cells treatment with EPC-K1 repressed NF-kappaB-dependent activation of the human immunodeficiency virus 1 promoter. In contrast, TNFalpha-induced activation of the human immunodeficiency virus 1 promoter was not completely inhibited by either treatment with vitamin E or vitamin C. We, thus, suggest that EPC-K1 is considered to be one of the inhibitory agents of NF-kappaB.


Subject(s)
Antioxidants/pharmacology , Ascorbic Acid/analogs & derivatives , Free Radical Scavengers/pharmacology , Gene Expression Regulation, Viral/drug effects , HIV-1/drug effects , NF-kappa B/antagonists & inhibitors , Promoter Regions, Genetic/drug effects , Vitamin E/analogs & derivatives , Ascorbic Acid/pharmacology , Astrocytoma , DNA, Viral/metabolism , Dose-Response Relationship, Drug , Genes, Reporter/drug effects , HIV-1/genetics , Humans , NF-kappa B/genetics , Plasmids , Transcription, Genetic/drug effects , Transfection , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha , Vitamin E/pharmacology
12.
Mol Cell Biol ; 18(5): 2596-607, 1998 May.
Article in English | MEDLINE | ID: mdl-9566879

ABSTRACT

To release transcription factor NF-kappaB into the nucleus, the mammalian IkappaB molecules IkappaB alpha and IkappaB beta are inactivated by phosphorylation and proteolytic degradation. Both proteins contain conserved signal-responsive phosphorylation sites and have conserved ankyrin repeats. To confer specific physiological functions to members of the NF-kappaB/Rel family, the different IkappaB molecules could vary in their specific NF-kappaB/Rel factor binding activities and could respond differently to activation signals. We have demonstrated that both mechanisms apply to differential regulation of NF-kappaB function by IkappaB beta relative to IkappaB alpha. Via alternative RNA processing, human IkappaB beta gives rise to different protein isoforms. IkappaB beta1 and IkappaB beta2, the major forms in human cells, differ in their carboxy-terminal PEST sequences. IkappaB beta2 is the most abundant species in a number of human cell lines tested, whereas IkappaB beta1 is the only form detected in murine cells. These isoforms are indistinguishable in their binding preferences to cellular NF-kappaB/Rel homo- and heterodimers, which are distinct from those of IkappaB alpha, and both are constitutively phosphorylated. In unstimulated B cells, however, IkappaB beta1, but not IkappaB beta2, is found in the nucleus. Furthermore, the two forms differ markedly in their efficiency of proteolytic degradation after stimulation with several inducing agents tested. While IkappaB beta1 is nearly as responsive as IkappaB alpha, indicative of a shared activation mechanism, IkappaB beta2 is only weakly degraded and often not responsive at all. Alternative splicing of the IkappaB beta pre-mRNA may thus provide a means to selectively control the amount of IkappaB beta-bound NF-kappaB heteromers to be released under NF-kappaB stimulating conditions.


Subject(s)
Alternative Splicing , DNA-Binding Proteins/genetics , I-kappa B Proteins , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Amino Acid Sequence , B-Lymphocytes/metabolism , Cell Compartmentation , Cell Nucleus/metabolism , Dimerization , Gene Expression Regulation , Genetic Variation , Humans , Molecular Sequence Data , Phosphorylation , Protein Binding , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-rel , Signal Transduction , Transcription, Genetic
13.
Mol Cell Biol ; 18(3): 1266-74, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9488441

ABSTRACT

Gene activation by NF-kappaB/Rel transcription factors is modulated by synergistic or antagonistic interactions with other promoter-bound transcription factors. For example, Sp1 sites are often found in NF-kappaB-regulated genes, and Sp1 can activate certain promoters in synergism with NF-kappaB through nonoverlapping binding sites. Here we report that Sp1 acts directly through a subset of NF-kappaB binding sites. The DNA binding affinity of Sp1 to these NF-kappaB sites, as determined by their relative dissociation constants and their relative efficiencies as competitor DNAs or as binding site probes, is in the order of that for a consensus GC box Sp1 site. In contrast, NF-kappaB does not bind to a GC box Sp1 site. Sp1 can activate transcription through immunoglobulin kappa-chain enhancer or P-selectin promoter NF-kappaB sites. p50 homodimers replace Sp1 from the P-selectin promoter by binding site competition and thereby either inhibit basal Sp1-driven expression or, in concert with Bcl-3, stimulate expression. The interaction of Sp1 with NF-kappaB sites thus provides a means to keep an elevated basal expression of NF-kappaB-dependent genes in the absence of activated nuclear NF-kappaB/Rel.


Subject(s)
NF-kappa B/metabolism , Oligodeoxyribonucleotides/metabolism , Sp1 Transcription Factor/metabolism , Animals , Binding Sites , Cell Line , Consensus Sequence , DNA/metabolism , Drosophila/cytology , HeLa Cells , Humans , NF-kappa B/genetics , NF-kappa B p50 Subunit , Promoter Regions, Genetic , Sp1 Transcription Factor/genetics , Transcription Factor RelA , Transcriptional Activation
14.
J Periodontal Res ; 32(8): 634-45, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9409458

ABSTRACT

CD44 functions as a receptor for various extracellular matrices and plays crucial roles in homotypic and heterotypic cell-cell interactions. Recently, the molecular structure of CD44 has been extensively analyzed and multiple isoforms produced by alternative splicing of messenger RNA have been identified. In this study, we examined the expression of CD44 isoforms on different cell types isolated from periodontal tissue. In order to examine tissue differences in CD44 isoform expression, we established in vitro cell culture of human gingival fibroblasts (HGF), human periodontal ligament cells (HPDL) and human gingival epithelial cells (HGEC). These cells all expressed CD44 protein and messenger RNA. However, immunoprecipitation and Northern blot analysis revealed that HGEC expressed larger CD44 isoforms than HGF and HPDL. Reverse transcription-polymerase chain reaction with primers flanking the insertion site of alternatively spliced exons was used to study details of the heterogeneity. All cells examined expressed a major band in the absence of alternatively spliced exons and additional larger bands. In particular, HGEC contained more abundant high molecular mass species. In vitro stimulation by IL-1 beta, TNF alpha or phorbol 12-myristate 13-acetate induced an increase in total CD44 messenger RNA in HGF but not change in overall patterns of CD44 isoform expression. However, the isoform expression of HGEC was sensitive to cell density. The amount of larger isoform was decreased by culturing cells beyond confluence. These findings suggest that CD44 isoform expression is cell type-specifically regulated in periodontium and altered according to growth phase of HGEC.


Subject(s)
Alternative Splicing , Gingiva/immunology , Hyaluronan Receptors/genetics , Periodontal Ligament/immunology , Blotting, Northern , Cell Communication , Cell Count , Cell Cycle/genetics , Cells, Cultured , DNA Primers , Epithelial Cells/cytology , Epithelial Cells/immunology , Exons/genetics , Extracellular Matrix/immunology , Fibroblasts/cytology , Fibroblasts/immunology , Gene Expression Regulation , Gingiva/cytology , Humans , Hyaluronan Receptors/analysis , Hyaluronan Receptors/classification , Interleukin-1/pharmacology , Periodontal Ligament/cytology , Polymerase Chain Reaction , Precipitin Tests , RNA, Messenger/genetics , Tetradecanoylphorbol Acetate/pharmacology , Transcription, Genetic , Tumor Necrosis Factor-alpha/pharmacology
15.
Carcinogenesis ; 17(3): 427-33, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8631127

ABSTRACT

We studied the effects of bile acids on inducibility of the transcription factor AP-1 in human colon carcinoma LoVo cells. Firstly, cells were treated with chenodeoxycholic acid and the nuclear extracts from those cells were processed by electrophoretic mobility shift assays to analyze nuclear AP-1 DNA-binding activity. We demonstrated that chenodeoxycholic acid induced AP-1 DNA-binding activity in a dose- and time-dependent fashion. Antibody supershift experiments clearly revealed that the majority of protein components in induced AP-1 DNA-binding activity were the products of oncogenes c-fos and c-jun. On the other hand, DNA-binding activity in the nuclear extracts for either NF kappa B, Sp1, or ATF/CREB was not affected by bile acids, suggesting that the effect of bile acids was rather specific for AP-1. Transient transfection experiments supported this notion: expression of the AP-1-luciferase reporter construct was induced by bile acids in a dose-dependent manner, and expression of either reporter construct for NF kappa B, Sp1, or ATF/CREB was not influenced by treatment of the cells with bile acids. We also demonstrated that those bile acids efficiently activated AP-1-dependent promoter in DLD-1 cells, which (as well as LoVo cells), are derived from colon adenocarcinoma, but not in COLO320DM cells which are from colon carcinoid tumor. Thus, we may indicate that bile acids exclusively induce nuclear AP-1 activity in colon adenocarcinoma cells.


Subject(s)
Adenocarcinoma/metabolism , Bile Acids and Salts/pharmacology , Cholagogues and Choleretics/pharmacology , Colonic Neoplasms/metabolism , DNA, Neoplasm/drug effects , DNA-Binding Proteins , Protein Kinase C/biosynthesis , Transcription Factor AP-1/metabolism , Activating Transcription Factor 1 , Base Sequence , Chenodeoxycholic Acid/pharmacology , Cholic Acid , Cholic Acids/pharmacology , DNA Primers/genetics , DNA, Neoplasm/metabolism , Deoxycholic Acid/pharmacology , Enzyme Activation , Gene Expression Regulation/drug effects , Genetic Vectors/genetics , Humans , Lithocholic Acid/pharmacology , Molecular Sequence Data , NF-kappa B/metabolism , Podophyllin/analogs & derivatives , Podophyllin/metabolism , Podophyllotoxin/analogs & derivatives , Tetradecanoylphorbol Acetate/pharmacology , Transcription Factor AP-1/genetics , Transcription Factors/metabolism , Tumor Cells, Cultured , Ursodeoxycholic Acid/pharmacology
16.
J Gastroenterol ; 31(1): 55-60, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8808429

ABSTRACT

We investigated the effect of ursodeoxycholic acid on major histocompatibility complex class I gene expression in cultured human hepatoma cells. Ursodeoxycholic acid, which is now being used for the treatment of various autoimmune liver diseases, paradoxically increased the mRNA level of major histocompatibility complex class I. However, endogenous bile acids, for example, chenodeoxycholic acid, increased major histocompatibility complex class I mRNA expression more strongly compared with ursodeoxycholic acid. Concerning the interplay between ursodeoxycholic and chenodeoxycholic acids, these bile acids additively induced major histocompatibility complex class I mRNA expression. In contrast, when the total concentration of ursodeoxycholic and chenodeoxycholic acids was kept constant, the expression of major histocompatibility complex class I mRNA appeared to decrease in a dose-dependent manner with an increasing ratio of ursodeoxycholic acid. These findings indicate that the beneficial action of ursodeoxycholic acid may be related to this relative decrease in major histocompatibility complex class I gene expression.


Subject(s)
Carcinoma, Hepatocellular/immunology , Chenodeoxycholic Acid/pharmacology , Histocompatibility Antigens Class I/drug effects , Liver Neoplasms/immunology , Ursodeoxycholic Acid/pharmacology , Blotting, Northern , Chenodeoxycholic Acid/administration & dosage , Gene Expression/drug effects , Histocompatibility Antigens Class I/genetics , Humans , RNA, Messenger/analysis , Tumor Cells, Cultured , Ursodeoxycholic Acid/administration & dosage
17.
J Immunol ; 156(4): 1601-8, 1996 Feb 15.
Article in English | MEDLINE | ID: mdl-8568266

ABSTRACT

The therapeutic effectiveness of ursodeoxycholic acid (UDCA) for various autoimmune liver diseases strongly indicates that UDCA possesses immunomodulatory activities. Experimental evidence also supports this notion, since, for example, UDCA has been shown to suppress secretion of IL-2, IL-4, and IFN-gamma from activated T lymphocytes, and Ig production from B lymphocytes. To investigate the mechanical background of UDCA-mediated immunomodulation, we asked whether UDCA interacts with the intracellular signal transduction pathway, especially whether it is involved in immunosuppressive glucocorticoid hormone action. For this purpose, we used a cloned Chinese hamster ovary cell line, CHOpMTGR, in which glucocorticoid receptor cDNA was stably integrated. In immunocytochemical analysis, we found that treatment with UDCA promoted the nuclear translocation of the glucocorticoid receptor in a ligand-independent fashion, which was further confirmed by immunoprecipitation assays. Moreover, the translocated glucocorticoid receptor demonstrated sequence-specific DNA binding activity. Transient transfection experiments revealed that treatment of the cells with UDCA marginally enhanced glucocorticoid-responsive gene expression. We also showed that UDCA suppressed IFN-gamma-mediated induction of MHC class II gene expression via the glucocorticoid receptor-mediated pathway. Together, UDCA-dependent promotion of translocation of the glucocorticoid receptor may be associated with, at least in part, its immunomodulatory action through glucocorticoid receptor-mediated gene regulation.


Subject(s)
Adjuvants, Immunologic/pharmacology , Receptors, Glucocorticoid/metabolism , Ursodeoxycholic Acid/pharmacology , Animals , Base Sequence , CHO Cells , Cell Compartmentation , Cricetinae , DNA-Binding Proteins/metabolism , Dexamethasone/pharmacology , Down-Regulation , Fluorescent Antibody Technique, Indirect , Gene Expression Regulation , Genes, MHC Class II , Glucocorticoids/pharmacology , Interferon-gamma/pharmacology , Ligands , Molecular Sequence Data , RNA, Messenger/genetics , Recombinant Proteins , Signal Transduction , Transcription, Genetic
18.
Diabetes Res Clin Pract ; 28(3): 151-9, 1995 Jun.
Article in English | MEDLINE | ID: mdl-8529493

ABSTRACT

We investigated metabolic and pathological changes in the peripheral nerve of the spontaneous-onset diabetic Chinese hamster. Electrophysiological examination revealed that the motor nerve conduction velocity was significantly decreased at 10 months and afterwards, however, the F-wave latency was significantly increased at 5 months and afterwards. Concerning sciatic nerve contents of sorbitol, myo- and scyllo-inositol, the content of sorbitol was not significantly increased at 5 months, but, myo- and scyllo-inositol were significantly decreased at 5 months and thereafter. At 10 and 15 months, however, sciatic nerve content of sorbitol was significantly increased. On morphological examination, loss of large myelinated fiber and reciprocal increase in degenerative fiber were also seen in sciatic nerve, but not in tibial nerve, at 5 months. At 15 months, these morphological changes were also found in the tibial as well as the sciatic nerve. Thus, we may hypothesize that F-wave latency is useful in the detection of initial diabetic neuropathy, and that the initial pathological changes in diabetic neuropathy of diabetic Chinese hamsters are predominantly found in the proximal site of peripheral nerves.


Subject(s)
Diabetes Mellitus, Type 2/physiopathology , Diabetic Neuropathies/physiopathology , Tibial Nerve/physiopathology , Aging , Animals , Cricetinae , Cricetulus , Electrophysiology , Female , Inositol/metabolism , Male , Motor Neurons/physiology , Neural Conduction , Reference Values , Sciatic Nerve/physiology , Sciatic Nerve/physiopathology , Sorbitol/metabolism , Tibial Nerve/growth & development , Tibial Nerve/physiology
19.
Biochem Biophys Res Commun ; 208(3): 935-42, 1995 Mar 28.
Article in English | MEDLINE | ID: mdl-7702623

ABSTRACT

We investigated the effect of bile acids on major histocompatibility complex (MHC) class I gene expression in the cultured human hepatoma cell HepG2. Not only chenodeoxycholic acid, but its stereoisomer ursodeoxycholic acid as well, increased steady state level of MHC class I mRNA. When various bile acids were studied, inducibility of MHC class I mRNA was closely associated with the hydrophobicity of the corresponding bile acids. Pretreatment of the cells with a protein kinase C (PKC) inhibitor H7 suppressed induction of MHC class I mRNA by those bile acids. Furthermore, treatment of the cells with chenodeoxycholic acid significantly induced translocation of PKC from cytosol to membrane. In summary, our data strongly indicate up-regulatory effect of bile acids on MHC class I mRNA expression, most probably via activation of PKC-dependent pathway.


Subject(s)
Bile Acids and Salts/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Genes, MHC Class I , Protein Kinase C/metabolism , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine , Carcinoma, Hepatocellular , Cell Line , Cell Membrane/metabolism , Chenodeoxycholic Acid/pharmacology , Cytosol/metabolism , Dose-Response Relationship, Drug , Histocompatibility Antigens Class I/biosynthesis , Humans , Isoquinolines/pharmacology , Kinetics , Liver Neoplasms , Piperazines/pharmacology , Protein Kinase C/antagonists & inhibitors , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Tetradecanoylphorbol Acetate/pharmacology , Tumor Cells, Cultured
20.
Endocr J ; 41(6): 623-30, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7704085

ABSTRACT

One of the determinants of cellular responsiveness to glucocorticoid hormone is the concentration of the receptor protein. It is well-known that cellular receptor levels are down-regulated by the cognate ligands, but the biological significance of this homologous down-regulation of the receptor has not yet been completely understood. We showed that in human histiocytic lymphoma cell line U937 the cellular glucorticoid receptor was homologously down-regulated by means of both ligand binding and Western immunoblot experiments. Reduction of the receptor was saturable, and the receptor levels tended to return to the levels before treatment after 3-day culture in the presence of the hormone. Next, using the cells which were pretreated with the hormone for 0 to 3 days, hormonal inducibility of the transiently-transfected reporter gene and the inhibitory effect of the hormone on cellular 3-O-methyl glucose uptake were determined. Hormonal inducibility of the reporter gene was progressively reduced, and thereafter tended to be restored, apparently in accordance with the cyclic change in amount of the receptor. The glucose uptake inhibiting effect of the hormone also revealed this cyclic pattern. In summary, in U937 cells glucocorticoid receptor was homologously down-regulated and may play a pivotal role in attenuating hormone responsiveness.


Subject(s)
Down-Regulation , Glucocorticoids/pharmacology , Lymphoma, Large B-Cell, Diffuse/metabolism , Receptors, Glucocorticoid/metabolism , 3-O-Methylglucose , Chloramphenicol O-Acetyltransferase/genetics , Dexamethasone/pharmacology , Genes, Reporter , Humans , Mammary Tumor Virus, Mouse/genetics , Methylglucosides/metabolism , Promoter Regions, Genetic , Receptors, Glucocorticoid/genetics , Recombinant Fusion Proteins/metabolism , Time Factors , Transfection , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL